Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Cimeio Therapeutics

Company Type: Therapeutics

Main focus: Gene editing and immunotherapy to transform haematopoietic stem cell transplantation

Company stage: Pre-clinical

Diseases: Genetic diseases, haematologic malignancies, and severe autoimmune disorders

Genome-editing tool: Prime editing

Funding stage: Series B

Location: Basel, Switzerland



Partners: Prime Medicine

Cimeio is an applied gene-editing and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs™ (SCIP), which has the potential to transform haematopoietic stem cell (HSC) transplantation. The company's technology platform is based upon the design and expression of modified variants of naturally occurring cell surface proteins in HSCs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. This technology has significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with genetic diseases, haematologic malignancies, and severe autoimmune disorders.


HashtagCimeio Therapeutics

Company: Cimeio Therapeutics
Search CRISPR Medicine